Total Rewards Specialist / Senior Specialist
About the job
- A solid understanding of compensation and benefits concepts and their administrative management is required.
- The ability to work autonomously with limited supervision is required.
- The candidate must be able to apply prior experience in compensation, benefits, and rewards to new activities or problems.
- Advanced Excel proficiency is required.
- The candidate must be able to interpret complex data sets and identify key trends.
- The candidate must be able to work effectively in ambiguous environments and adapt their approach to changing priorities or context.
- The candidate must collaborate effectively with the Reward team and Business Human Resources and Talent Acquisition stakeholders.
- Serve as the first point of contact for routine requests from Business Human Resources and Talent Acquisition teams.
- Conduct job evaluations and market benchmarks to determine appropriate job classification and compensation levels.
- Build and maintain market reference data in the Comp Analyst benchmarking tool.
- Own annual compensation and benefits survey submissions for the assigned client group or geographic area.
- Develop internal and external compensation proposals for hires, promotions, BSAs, lateral moves, and demotions; advise Business Human Resources and Talent Acquisition teams on sign-on bonuses and long-term incentive buyout calculations.
- Conduct periodic compensation data audits in Workday.
- Provide ad hoc support to Total Rewards Consultants for internal and market analysis requests.
- Support production of pay equity reporting as needed.
- Lead analytical and operational support for the annual rewards planning process for the assigned client group or region.
- Conduct annual data audits, including proration, leave, splitters, and full-time-equivalent status checks.
- Contribute to system testing for RPT.
- Complete RPT co-planner files and supplemental or override files.
- Prepare country salary structures.
- Collect market data and develop annual salary increase recommendations for each country.
- Manage and finalize annual renewals of benefits policies and contracts for small and medium-sized business units or countries in the assigned regional cluster.
- Support the Total Rewards Consultant with annual renewals of benefits policies and contracts for the assigned large business unit or country.
About the company
AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.
Company Size
10,001+
Company Stage
IPO
Headquarters
North Chicago, Illinois
Founded
1888
Get referred to AbbVie
See people who can refer or advise you
Simplify's Take
What believers are saying
- Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
- EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
- JUVMO launches in October 2026, adding a fresh neuroscience revenue line.
What critics are saying
- Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
- Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
- Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.
What makes AbbVie unique
- Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
- JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
- AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Remote Work Options
- Flexible Work Hours
- Professional Development Budget